Ayala Pharma under pressure on underwhelming AL101 data in type of cancer affecting the glandular tissues [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
Healthcare|On the MoveAyala Pharma under pressure on underwhelming AL101 data in type of cancer affecting the glandular tissuesSep. 18, 2020 10:49 AM ETAyala Pharmaceuticals, Inc. (AYLA)Vandana SinghAyala Pharmaceuticals (-10.2%interim dataPhase 2 ACCURACY trialThe trial is evaluating the safety and efficacy of AL101 as monotherapy in two dose cohorts, 4mg once per week and 6mg QW. Dosing for the 6mg QW cohort commenced in March and enrollment is underway for up to 42 subjects.As of July 30, of the 45 subjects enrolled in the 4 mg QW cohort, 40 were evaluable. Partial responses were observed in six subjects (15%) and stable disease was observed in 21 subjects (53%), yielding a 68% disease control rate; ~40% of evaluable patients remained on drug for at least six months after entering the study with disease progression, including two patients treated beyond progression.On safety front, the company says AL101 was generally well-tolerated and that most adverse events were mild to moderat
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights [Reuters]Reuters
- Inhalation CDMO Global Research Report 2024-2033: Integration of AI and ML Enhances Capabilities, Biopharmaceutical Inhalation Therapies Rapidly Expand, Patient-Centric Solutions Take Center Stage [Yahoo! Finance]Yahoo! Finance
- Obsessive-Compulsive Disorder (OCD) Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status [Yahoo! Finance]Yahoo! Finance
- UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology [Yahoo! Finance]Yahoo! Finance
- GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 1/30/24 - Beat
PFE
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form PX14A6G
- PFE's page on the SEC website